239 Results for "

neutralization

" in MedChemExpress (MCE) Product Catalog:
Products (239)

239 Results for "neutralization" in MCE Product Catalog:

Cat. No.: HY-P990221

Target:  

Interleukin Related

Research Areas:  

Infection Neurological Disease Cancer

Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-17F. Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) can neutralize IL-17. Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) can be used for the researches of cancer, infection and neurological disease, such as Alzheimer’s disease (AD) and pancreatic cancer .
loading...
    loading...
Cat. No.: HY-P990232

Target:  

IFNAR

Research Areas:  

Others

Anti-Mouse IFNγRα/CD119 Antibody (2E2) is an Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse IFNγRα/CD119. Anti-Mouse IFNγRα/CD119 Antibody (2E2) reacts with the mouse IFNγR (interferon gamma receptor) α chain also known as CD119 and IFNγ receptor 1. Anti-Mouse IFNγRα/CD119 Antibody (2E2) is a non-neutralizing antibody and does not block the binding of IFNγ to the receptor. Anti-Mouse IFNγRα/CD119 Antibody (2E2) can be used for detections of western blot, flow cytometry and immunoprecipitation .
loading...
    loading...
Cat. No.: HY-P991097
Synonyms: PM-8002; BNT-327

Target:  

VEGFR PD-1/PD-L1

Research Areas:  

Cancer

Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .
loading...
    loading...
Cat. No.: HY-P99148

Target:  

TNF Receptor

Anti-Mouse TNF alpha Antibody (TN3-19.12) is an anti-mouse TNF alpha IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse TNF alpha Antibody (TN3-19.12) neutralizes cytotoxic activity in supernatants obtained from LNC-8 cells. Anti-Mouse TNF alpha Antibody (TN3-19.12) reduces the symptoms and severity of EAE (experimental allergic encephalomyelitis) in LNC-8 cells xenograft mice models. Anti-Mouse TNF alpha Antibody (TN3-19.12) prevents diabetes in NOD mice. Anti-Mouse TNF alpha Antibody (TN3-19.12) shows apparent radiosensitizing effect in CD2F1 mice .
loading...
    loading...
Cat. No.: HY-P992482
VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease .
loading...
    loading...
Cat. No.: HY-P10427
DV1 is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases .
loading...
    loading...
Cat. No.: HY-P990234
Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse ICOSL/CD275. Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) is a chimeric antibody of the original HK5.3 antibody (HY-P990123). Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) contains the LALA-PG mutation region. Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) can neutralize ICOSL. Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) can be used for researches of inflammation and infection.
loading...
    loading...
Cat. No.: HY-P990235
Anti-Mouse ICOSL/CD275 (D265A) Antibody (HK5.3) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse ICOSL/CD275. Anti-Mouse ICOSL/CD275 (D265A) Antibody (HK5.3) is a chimeric antibody of the original HK5.3 antibody (HY-P990123). Anti-Mouse ICOSL/CD275 (D265A) Antibody (HK5.3) contains the D265A mutation region. Anti-Mouse ICOSL/CD275 (D265A) Antibody (HK5.3) can neutralize ICOSL. Anti-Mouse ICOSL/CD275 (D265A) Antibody (HK5.3) can be used for researches of inflammation and infection.
loading...
    loading...
Cat. No.: HY-P990552A

Target:  

PAI-1 Integrin

Research Areas:  

Cancer

huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .
loading...
    loading...
Cat. No.: HY-P990957
CAS No.: 2764727-44-6
Synonyms: BCA-101; FMAB2

Target:  

EGFR TGF-beta/Smad

Research Areas:  

Inflammation/Immunology Cancer

Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a Kd of 2.58 nM against EGFR and a Kd of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .
loading...
    loading...
Cat. No.: HY-P991628
Synonyms: PF-08634404

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1 signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .
loading...
    loading...
Cat. No.: HY-113512
CAS No.: 90780-52-2
Purity:  98.8%
17-HDHA is a DHA-derived specialized pro-resolving mediator (SPM). 17-HDHA inhibits NF-κB activation by activating PPARγ and upregulating IκBα, targets FPR2 and Bcl-6, and also acts as a precursor of RvD1 and PD1. 17-HDHA inhibits pulmonary artery smooth muscle cell proliferation, regulates the expression of adiponectin, GLUT-4 and inflammatory cytokines, suppresses IgE production by B cells and promotes antibody secretion. 17-HDHA reduces adipose tissue inflammation, improves insulin sensitivity and glucose tolerance, alleviates pathological processes associated with pulmonary hypertension, and enhances antibody responses and virus neutralizing activity against influenza HA. 17-HDHA can be used in research related to obesity-associated inflammation, insulin resistance, glucose intolerance, pulmonary hypertension and influenza virus infection .
loading...
    loading...
Cat. No.: HY-P10427A
Target:  

CXCR Dengue Virus

Research Areas:  

Infection

DV1 TFA is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 TFA inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 TFA not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 TFA induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 TFA has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases .
loading...
    loading...
Cat. No.: HY-P5107A
Synonyms: LMWP acetate; TDSP5 acetate
Target:  

VEGFR

Research Areas:  

Cancer

Low molecular weight protamine acetate (LMWP acetate;TDSP5 acetate) is a truncated arginine-rich protamine peptide, which also acts as an antidote for heparin/low molecular weight heparin and a cell-penetrating delivery vector. Low molecular weight protamine acetate neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities. Low molecular weight protamine acetate translocates across mammalian cell membranes, delivers conjugated impermeable molecules through tumor tissues, enhances the skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine acetate retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine acetate can be used in studies related to colon cancer, skin wounds and diabetic skin wounds .
loading...
    loading...
Cat. No.: HY-P991753

Target:  

CXCR

Research Areas:  

Infection

Anti-Mouse CCL5 Antibody (R6G9) is a neutralizing agent that binds to CCL5 to inhibit its chemotactic activity towards CD4 + T cells .Anti-Mouse CCL5 Antibody (R6G9) does not suppress CD4 + T cell migration towards infection-derived liver cells, reduce CD4 + T cell hepatic accumulation, or impair CD4 + T cell migratory capacity .Anti-Mouse CCL5 Antibody (R6G9) serves as a tool to assess CCL5’s role in in vivo target cell killing by LCMV-specific CD8 + effector T cells .Anti-Mouse CCL5 Antibody (R6G9) can be used for the research of malaria infection and lymphocytic choriomeningitis virus infection .
loading...
    loading...
Cat. No.: HY-P992518

Target:  

VEGFR PD-1/PD-L1

Research Areas:  

Cancer

Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .
loading...
    loading...
Cat. No.: HY-W043748
CAS No.: 38862-24-7
Synonyms: N-Succinimidyl acrylate
Research Areas:  

Others

2,5-Dioxopyrrolidin-1-yl acrylate (N-Succinimidyl acrylate) is a lysine residue modifier and coupling monomer. 2,5-Dioxopyrrolidin-1-yl acrylate covalently modifies the primary amines of lysine residues on monoclonal anti-horseradish peroxidase IgG antibodies, neutralizes positive charges and replaces them with low-affinity acrylate groups. 2,5-Dioxopyrrolidin-1-yl acrylate inhibits the formation of rapid hard coronas on citrate-coated gold nanoparticles, induces antibody unfolding and loss of antigen-binding function, but does not affect the antigen-binding function of antibodies in free solution. 2,5-Dioxopyrrolidin-1-yl acrylate reacts with the ε-amino groups on lysine residues of L-asparaginase, introduces vinyl groups and generates N-hydroxysuccinimide. 2,5-Dioxopyrrolidin-1-yl acrylate regulates the activity of L-asparaginase .
loading...
    loading...
Cat. No.: HY-W145481A
CAS No.: 11078-30-1
Synonyms: Carob galactomannan
D-Galacto-D-mannan (Carob galactomannan) is an orally active Dectin-2 agonist. D-Galacto-D-mannan exerts antioxidant activity against hydroxyl radical generation. D-Galacto-D-mannan activates Dectin-2 to trigger downstream signaling pathways, promote the expression of immunoregulatory molecules, coordinate innate and adaptive immune responses, and inhibit excessive inflammatory responses by upregulating the expression of Sirtuin 1. When used as a vaccine adjuvant, D-Galacto-D-mannan induces cellular and humoral immune responses, promotes IFNγ secretion, increases antibody levels and virus neutralization titers, and elevates the levels of immunoglobulin G and A. D-Galacto-D-mannan can serve as an adjuvant for foot-and-mouth disease vaccines, enhance the vaccine-mediated ability of hosts to defend against viral infection in mice, and reduce local side effects at the inoculation site in pigs. D-Galacto-D-mannan can be used in the research of inflammatory and immune diseases, such as foot-and-mouth disease .
loading...
    loading...
Cat. No.: HY-120078
CAS No.: 1845753-81-2
Target:  

Phospholipase

Research Areas:  

Cardiovascular Disease

AZD2716 is an orally active secretory phospholipase A2 (sPLA2) inhibitor. AZD2716 inhibits human GIIA sPLA2 (IC50=10 nM), human GV sPLA2 (IC50=40 nM), human GX sPLA2 (IC50=400 nM), snake venom sPLA2 (IC50=2 pM), and snake (Bothrops jararacussu) Lys49-PLA2-like toxin (Kd=110 μM). AZD2716 inhibits sPLA2 isoforms IIa, V, X, snake venom sPLA2s, and snake venom Lys49-PLA2-like toxin myotoxic activity via hydrophobic channel binding. AZD2716 suppresses GIIA sPLA2 production, neutralizes snake venom-induced myotoxicity, and improves survival in envenomed mice. AZD2716 can be used for the research of coronary artery disease, atherosclerosis, and snakebite envenoming .
loading...
    loading...